Novartis dismisses 322 more staffers based out of US headquarters
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink…
Novartis CEO eyes 2026 growth despite record patent cliff
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s…
Novartis stands by $5B Pluvicto goal despite EU regulatory setback
Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as…
Novartis plans 114 more job cuts at East Hanover HQ
Listen to this article The basics: Novartis to eliminate 114 positions at East Hanover HQ Layoffs part of…
Novartis misses quarterly sales, profit estimates as Entresto generics hit growth
SWISS drugmaker Novartis reported first-quarter core operating profit and sales below market expectations on Tuesday, as generic competition…
Novartis misses quarterly sales, profit estimates as Entresto generics hit growth
April 28 (Reuters) – Swiss drugmaker Novartis reported first-quarter core operating profit and sales below market expectations on…
Novartis Faces Sales and Profit Decline Amid Entresto Generic Competition, ETPharma
London: Swiss drugmaker Novartis reported first-quarter core operating profit and sales below market expectations on Tuesday, as generic…
Should You Buy Novartis Stock Before October 28?
Switzerland-based global healthcare company Novartis (NVS) is gaining momentum this year, thanks to solid pipeline execution, new regulatory…
Abusive pharma patents: Roche’s “mAb” empire
This summer, Roche followed the same playbook for another of its cancer drugs, Lunsumio. As of early November,…